At the news
? NEUTRALIMPACT 6/10 PRESS-RELEASE filed May 12, 2026 at 07:00 ET
Sionna reported Q1 2026 GAAP EPS of -$0.60, a 3.2% beat vs consensus of -$0.62, but net loss widened to $26.8M from $16.5M a year ago on higher R&D and G&A spending. The key catalyst is the on-track summer 2026 topline data from the Phase 2a PreciSION CF trial and Phase 1 dual-combination trial, which will determine whether SION-719 can expand CF treatment options. Cash of $289.9M funds operations into 2028, removing near-term dilution risk.
- Q1 2026 GAAP EPS -$0.60 vs consensus -$0.62 (3.2% beat)
- Net loss widened to $26.8M from $16.5M YoY on higher R&D ($19.0M vs $13.7M) and G&A ($10.6M vs $6.0M)
- Phase 2a PreciSION CF trial of SION-719 enrollment completed; topline data expected summer 2026
- Phase 1 dual-combination trial of SION-451 with SION-2222 and SION-109 on track for summer 2026 topline data
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access